Article Text

PDF
How safe are ACE inhibitors for heart failure in children?
  1. Marijke van der Meulen1,
  2. Michiel Dalinghaus1,
  3. Michael Burch2,
  4. Andras Szatmari3,
  5. Cristina Castro Diez4,
  6. Feras Khalil4,
  7. Vanessa Swoboda5,
  8. Johannes Breur6,
  9. Milica Bajcetic7,
  10. Ida Jovanovic8,
  11. Florian B Lagler9,
  12. Ingrid Klingmann10,
  13. Stephanie Laeer11,
  14. Saskia N de Wildt12
  1. 1Department of Pediatric Cardiology, Erasmus MC - Sophia, Rotterdam, The Netherlands
  2. 2Cardiothoracic Unit, Great Ormond Street Hospital, London, UK
  3. 3Department of Pediatric Cardiology, Göttsegen Gyorgy Hungarian Institute of Cardiology, Budapest, Hungary
  4. 4Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine Universität Düsseldorf, Dusseldorf, Germany
  5. 5Medical University of Vienna, Vienna, Austria
  6. 6Department of Pediatric Cardiology, Wilhelmina Children’s Hospital University Medical Center, Utrecht, Utrecht, The Netherlands
  7. 7Univerzitetska Dečja Klinika, Belgrade, Serbia
  8. 8Clinical Pharmacology Unit, University Children’s Hospital, Belgrade, Serbia
  9. 9Paracelsus Medizinische Privatuniversitat, Salzburg, Austria
  10. 10Pharmaplex bvba, Wezembeek_Oppem, Belgium
  11. 11Department of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-Universität, Düsseldorf, Germany
  12. 12Department of Pharmacology and Toxicology, Radboud University, Nijmegen, The Netherlands
  1. Correspondence to Dr Michiel Dalinghaus, Paediatric Cardiologist, Erasmus Medical Centre, Sophia Children’s Hospital, Rotterdam, The Netherlands; m.dalinghaus{at}erasmusmc.nl

Statistics from Altmetric.com

Scenario

A boy aged 1 year, recently diagnosed with dilated cardiomyopathy, has to be treated with enalapril according to the heart failure protocol. The physician wants to know which adverse events she can expect.

Structured clinical question

What are the potential adverse events related to administration of an ACE inhibitor to children with heart failure? What is the prevalence and what are the possible risk factors?

Search

Secondary sources—nil

Electronic databases (PubMed/Medline and Embase) and reference lists of relevant articles were searched with the following strategy: ’angiotensin-converting enzyme inhibitors’ and ‘heart failure’ and ‘children’. The search yielded 415 individual articles, of which 14 were identified as relevant.

Commentary

Heart failure is an important cause of morbidity and mortality in children.1

It is commonly treated with ACE inhibitors (ACE-i) despite the lack of evidence on its efficacy.2 This treatment is based on the assumption that blocking of the renin-angiotensin-aldosterone system has a positive effect on morbidity and mortality, as it does in adults with heart failure.3–6 In adults, the most prevalent adverse events (AEs) related to the use of ACER-i are renal failure,7 8 hypotension,9 10 hyperkalemia,9 11 cough12 and angioedema.13 It is assumed that the safety profile of ACE-i differs for children and differs from that for adults, and for children of different ages, as growth and development contribute to variation in the disposition and effect of most drugs administered …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.